SALEM, N.H. — AgaMatrix Inc. and sanofi-aventis have signed a long-term agreement for the development, supply and commercialization of blood glucose monitoring solutions.
Under the agreement, announced Wednesday, AgaMatrix and sanofi-aventis will co-develop solutions in diabetes management that incorporate AgaMatrix’s WaveSense technology. Through its Global Diabetes Division, sanofi-aventis then will commercialize integrated solutions for patients with diabetes, along with its current insulins and delivery devices.
Sanofi-aventis’ insulin and device portfolio include Lantus, a basal insulin that the pharmaceutical giant said is the world’s top-prescribed insulin, and Apidra, a fast-acting insulin, plus its SoloSTAR and ClikSTAR delivery pens.
AgaMatrix said its proprietary WaveSense technology personalizes each test to provide world-class accuracy by employing a method called dynamic electrochemistry, which detects and corrects for errors caused by differences in blood samples, manufacturing variations and environmental conditions. The company added that tests are fast, require very little blood, and don’t require coding.
"Our unwavering message to patients, health care professionals and industry leaders has been that people with diabetes need more accurate blood glucose monitors and that our WaveSense technology delivers high accuracy. So naturally we are thrilled to find a partner that shares these beliefs," stated Sonny Vu and Sridhar Iyengar, co-founders of AgaMatrix. "With sanofi-aventis’ global presence and sterling reputation, we believe this partnership will enable us to finally fulfill our original vision of making high-accuracy blood glucose testing easily available to patients worldwide."
Sanofi-aventis said that it selected AgaMatrix as its global glucose monitoring partner based on the company’s accurate, innovative products.
"In building our Global Diabetes Division, our objectives included conducting an exhaustive search for potential partners that have excellent core science, are highly innovative and have the potential to develop a broad range of products. With AgaMatrix, we’ve found a company that can meet all three objectives in the blood glucose monitoring category," commented Eric Petreto, vice president of device strategy of the sanofi-aventis Global Diabetes Division.
Salem, N.H.-based AgaMatrix develops, manufactures and markets a line of blood glucose meters, biosensors (strips) and diabetes management software. Its products include the WaveSense KeyNote, Presto and WaveSense Jazz blood glucose monitors and the WaveSense Diabetes Manager iPhone App.
Comments are closed.